



Ontario Health

Cancer Care Ontario

TO: Regional Cancer Programs
Regional Vice Presidents
Ontario Cancer Leads
Systemic Treatment Program Committee
Pathology and Laboratory Medicine Program Regional Leads
Ontario Lab Directors
Molecular Oncology Testing Advisory Committee

FROM: Jennifer Hart, Manager, Pathology & Laboratory Medicine Program

CC: Dr. Aaron Pollett, Provincial Head, Pathology & Laboratory Medicine Program
Elaine Meertens, Interim Executive Lead, Clinical Institutes & Quality Programs

DATE: June 1, 2021

SUBJECT: Comprehensive Cancer Testing at Diagnosis - Wave 1 Implementation

PLEASE DISTRIBUTE TO ALL CANCER PROVIDERS IN YOUR NETWORK

Effective June 1, 2021 Ontario Health – Cancer Care Ontario (OH-CCO) is implementing comprehensive cancer testing at diagnosis for **Uveal Melanoma** and **Head and Neck** cancers, and expanded testing for **Lung Cancer, Colorectal and Small Bowel** cancers, and **Melanoma** to include additional markers. Please see **Appendix 1** for information about testing indications and testing sites.

This testing represents Wave 1 of a larger initiative to implement comprehensive cancer testing at diagnosis to support patient management. Implementation will occur in three waves - June 1, August 1 and October 1 2021 and includes funding for new testing as well as for the expansion of testing among currently funded disease sites.

Over the past 15 months we have worked closely with labs and oncologists to develop an evidence-based approach to identify diagnostic, predictive and prognostic markers to be tested at diagnosis. The list of markers and indications will be monitored and adjusted over time as evidence emerges to support clinical use. With this initiative the extent and volume of testing will increase. Patients will have access to testing that is standardized, comprehensive, evidence based and coordinated across the province.

Information about Wave 2 and 3 will be shared with you in the coming weeks.

Contact Us:

If you have any questions regarding Wave 1 Testing, please contact Goran Klaric, Senior Specialist, Pathology & Laboratory Medicine Program at OH-CCO_PLMPCCO@ontariohealth.ca

Appendix 1: Indications and Testing Sites effective June 1 2021

Uveal Melanoma (New)

Uveal Melanoma	Uveal Melanoma
Testing Indication: <ul style="list-style-type: none"> • Reflex testing on newly diagnosed tumours with uveal melanoma <ul style="list-style-type: none"> ○ GNAQ, GNA11 	<ul style="list-style-type: none"> • London Health Sciences Centre • Hamilton Health Sciences/ St. Joseph's Healthcare • William Osler Health System • Sunnybrook Health Sciences Centre • Mount Sinai Hospital • University Health Network • Kingston Health Sciences Centre

Head and Neck (New)

Head and Neck Squamous Cell Carcinoma	Testing Sites
Testing Indication: <ul style="list-style-type: none"> • Reflex testing on newly diagnosed tumours with metastatic, unresectable recurrent head and neck squamous cell carcinoma <ul style="list-style-type: none"> ○ PD-L1 	<ul style="list-style-type: none"> • London Health Sciences Centre • Hamilton Health Sciences/ St. Joseph's Healthcare • Trillium Health Partners - Credit Valley Site • William Osler Health System • Sunnybrook Health Sciences Centre • University Health Network • Kingston Health Sciences Centre • The Ottawa Hospital • Health Sciences North

Nasopharyngeal Carcinoma	Testing Sites
Testing Indication: <ul style="list-style-type: none"> • Testing to support diagnosis of nasopharyngeal carcinoma (newly diagnosed or suspected nasopharyngeal carcinoma) <ul style="list-style-type: none"> ○ EBER 	<ul style="list-style-type: none"> • London Health Sciences Centre • Trillium Health Partners - Credit Valley Site • William Osler Health System • Sunnybrook Health Sciences Centre • Mount Sinai Hospital • University Health Network • Unity Health - St. Michael's Hospital • Markham Stouffville Hospital • Kingston Health Sciences Centre • The Ottawa Hospital • Health Sciences North

Head and Neck Squamous Cell Carcinoma	Testing Sites
Testing Indication: <ul style="list-style-type: none"> • Newly diagnosed cases of squamous cell carcinoma where HPV cannot be determined from histology / p16 staining <ul style="list-style-type: none"> ○ HPV 	<ul style="list-style-type: none"> • Sunnybrook Health Sciences Centre • Mount Sinai Hospital • University Health Network • Markham Stouffville Hospital

Non-Small Cell Lung Cancer (NSCLC) (Expanded Testing)

Expanded Lung Cancer Testing	Testing Sites
<p>Testing Indications:</p> <ul style="list-style-type: none"> • Reflex testing on newly diagnosed cases of NSCLC (adenocarcinoma/non-squamous): <ul style="list-style-type: none"> ○ Effective June 1, 2021 – <i>minimum testing requirements</i> - (PD-L1, ALK, EGFR, ROS1, BRAF, MET (Met skipping), RET) ○ Effective September 1, 2021 - <i>minimum testing requirements</i> - (PD-L1, ALK, EGFR, ROS1, BRAF, MET (Met skipping), RET, FGFR1, HER2 (ERBB2), KRAS, PIK3CA, SMARCA4, NTRK) • Reflex testing on newly diagnosed cases of NSCLC (squamous): <ul style="list-style-type: none"> ○ PD-L1 	<ul style="list-style-type: none"> • London Health Sciences Centre • Hamilton Health Sciences/ St. Joseph's Healthcare • Trillium Health Partners Credit Valley Site • William Osler Health System • Sunnybrook Health Sciences Centre • University Health Network • Kingston Health Sciences Centre • The Ottawa Hospital • Health Sciences North

Melanoma (Expanded Testing)

Expanded Melanoma Testing	Testing Sites
<p>Testing Indication:</p> <ul style="list-style-type: none"> • Reflex testing on newly diagnosed cases of advanced*/metastatic Melanoma <ul style="list-style-type: none"> ○ BRAF, KIT, NRAS 	<ul style="list-style-type: none"> • London Health Sciences Centre • Hamilton Health Sciences/ St. Joseph's Healthcare • Trillium Health Partners Credit Valley Site • William Osler Health System • Sunnybrook Health Sciences Centre • University Health Network • Kingston Health Sciences Centre • The Ottawa Hospital • Health Sciences North

*For biomarker testing purposes, advanced is considered any melanoma >2mm in depth (pT3)

Colorectal and Small Bowel Cancer (Expanded Testing)

Expanded testing for Colorectal and Small Bowel Cancers	Testing Sites
<p>Testing Indication:</p> <ul style="list-style-type: none"> • Reflex testing on newly diagnosed cases advanced*/metastatic colorectal or small bowel carcinoma <ul style="list-style-type: none"> ○ BRAF, KRAS, NRAS ○ PIK3CA (optional for 21/22), PTEN (optional for 21/22) 	<ul style="list-style-type: none"> • London Health Sciences Centre • Hamilton Health Sciences/ St. Joseph's Healthcare • Trillium Health Partners Credit Valley Site • William Osler Health System • Sunnybrook Health Sciences Centre • Mount Sinai Hospital • University Health Network • Kingston Health Sciences Centre • The Ottawa Hospital • Health Sciences North

*For biomarker testing purposes, advanced is considered CRC/Small Bowel tumours Stage III and above